上海医药溴吡斯的明缓释片获批生产

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespamine sustained-release tablets, which are indicated for the treatment of myasthenia gravis [1] Group 1 - The product, Bromidespamine sustained-release tablets, was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The registration certificate number for the approved drug is 2025S03175 [1]